Assessment of acute antivascular effects of vandetanib with high-resolution dynamic contrast-enhanced computed tomographic imaging in a human colon tumor xenograft model in the nude rat.
Tumor size is not a reliable marker for the assessment of early antivascular effects of antiangiogenics. In the present study, we used 200-microm in-plane high-resolution dynamic contrast-enhanced computed tomography (DCE-CT) to noninvasively assess the immediate antivascular effects of vandetanib in a subcutaneous human colon cancer (LoVo) xenograft model in nude rats and to investigate correlation between changes in CT perfusion parameters and tumor volume or immunohistochemical end points. At 3 to 4 weeks after LoVo cell implantation, the animal was gavaged with either vandetanib (50 mg/kg) or vehicle twice (22 hours apart) and scanned with a preclinical DCE-CT scanner before (0 hour) and after treatment (24 hours). Quantitative maps of blood flow (BF) and volume (BV) of the tumor were calculated from the acquired DCE-CT images. The rats were divided into nonhypovascular, hypovascular, and combined (regardless of vascularity) groups. In the nonhypovascular group, significant decreases in both tumor BF and BV were observed in the vandetanib-treated rats compared with increases in the vehicle-treated rats. A significant decrease in BV was detected in the vandetanib-treated rats in the combined group as well. No differences in tumor growth, vascular endothelial growth factor expression, microvessel density, or apoptosis were observed between vandetanib- and vehicle-treated rats in all three groups. These results demonstrate that BF and BV imaging biomarkers from DCE-CT imaging can be used for rapid monitoring of immediate (24 hours after) antimicrovascular effects of vandetanib on tumors, even in the absence of significant changes of tumor volume or clinically relevant immunohistochemical end points.
Tai
Joo Ho
JH
Lawson Health Research Institute, St Joseph's Health Care London, London, Ontario, Canada.
Tessier
Jean
J
Ryan
Anderson J
AJ
Hoffman
Lisa
L
Chen
Xiaogang
X
Lee
Ting-Yim
TY
D000230:Adenocarcinoma / Q000098:blood supply / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D045744:Cell Line, Tumor; D003110:Colonic Neoplasms / Q000098:blood supply / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D003287:Contrast Media; D006801:Humans; D007089:Image Enhancement / Q000379:methods; D007700:Kinetics; D008297:Male; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000473:pathology; D010880:Piperidines / Q000494:pharmacology / Q000627:therapeutic use*; D011799:Quinazolines / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D011923:Rats, Nude; D013997:Time Factors; D014057:Tomography, X-Ray Computed / Q000379:methods*; D023041:Xenograft Model Antitumor Assays
D020533:Angiogenesis Inhibitors; D003287:Contrast Media; D010880:Piperidines; D011799:Quinazolines; C452423:vandetanib
J Comput Assist Tomogr. 2003 Sep-Oct;27(5):687-93
14501359
Am J Pathol. 1995 Jul;147(1):9-19
7541613
J Clin Oncol. 2003 Aug 1;21(15):2831-42
12807936
NMR Biomed. 2008 Jan;21(1):42-52
17458919
Am J Pathol. 2003 Jan;162(1):183-93
12507901
Nucl Med Biol. 2007 Jul;34(5):483-92
17591548
N Engl J Med. 2008 May 8;358(19):2039-49
18463380
Radiology. 2005 Mar;234(3):785-92
15734934
Nat Med. 2003 Jun;9(6):685-93
12778167
Br J Cancer. 2005 Jun;92 Suppl 1:S6-13
15928657
Mol Cancer Ther. 2004 Sep;3(9):1041-8
15367698
Mol Cancer Ther. 2007 Feb;6(2):471-83
17308046
Am J Pathol. 2004 Jul;165(1):35-52
15215160
Eur J Cancer. 2009 Jan;45(2):228-47
19097774
AJR Am J Roentgenol. 2009 Aug;193(2):304-13
19620425
N Engl J Med. 1991 Jan 3;324(1):1-8
1701519
Cancer. 1981 Jan 1;47(1):207-14
7459811
Radiology. 2007 Aug;244(2):486-93
17641369
AJR Am J Roentgenol. 2008 Jul;191(1):133-9
18562736
Q J Nucl Med. 2003 Sep;47(3):171-87
12897709
J Clin Oncol. 2005 Feb 10;23(5):1011-27
15585754
J Clin Oncol. 2007 Jul 20;25(21):3045-54
17634482
Neuroimage. 2008 Mar 1;40(1):26-34
18187345
Mol Cancer Ther. 2007 Aug;6(8):2198-208
17699717
J Natl Cancer Inst. 2002 Jun 19;94(12):883-93
12072542
Science. 2005 Jan 7;307(5706):58-62
15637262
Cancer Res. 2002 Aug 15;62(16):4645-55
12183421
Cancer Cell. 2005 Oct;8(4):269-71
16226701
Acad Radiol. 2000 Oct;7(10):840-50
11048881
Mol Imaging. 2004 Jul;3(3):149-58
15530250
Cancer. 2009 May 15;115(10 Suppl):2282-9
19402071
Radiology. 2008 Nov;249(2):510-7
18812560
Nat Clin Pract Oncol. 2006 Jan;3(1):24-40
16407877
Oncologist. 2008 Feb;13(2):120-5
18305056
Med Phys. 2007 Nov;34(11):4526-44
18072519
Nature. 2005 Dec 15;438(7070):932-6
16355210
N Engl J Med. 1995 Dec 28;333(26):1757-63
7491141
Science. 2006 May 26;312(5777):1171-5
16728631
Cancer Chemother Pharmacol. 2009 Sep;64(4):665-72
19184020
Invest Radiol. 2009 May;44(5):265-70
19346961
N Engl J Med. 1971 Nov 18;285(21):1182-6
4938153
Br J Radiol. 2003 Apr;76(904):220-31
12711641
Nat Med. 2004 Feb;10(2):145-7
14745444
Ann Oncol. 2009 Mar;20(3):486-91
19088171
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
10655437
Cancer Res. 1989 Jul 1;49(13):3506-12
2731172
Anticancer Drugs. 2007 Jun;18(5):569-79
17414626
Radiology. 2005 Oct;237(1):151-8
16183931
Brain. 1998 Jul;121 ( Pt 7):1369-79
9679787
Lung Cancer. 2001 Nov;34(2):233-41
11679182
Acad Radiol. 2000 Oct;7(10):800-11
11048878
J Comput Assist Tomogr. 2009 Jul-Aug;33(4):552-9
19638848
J Angiogenes Res. 2009 Sep 21;1:5
19946413
J Nucl Med. 1984 Sep;25(9):972-7
6088735